May 3, 2010
Shionogi and Eli Lilly Japan jointly launched on April 19 the serotonin-noradrenaline reuptake inhibitor (SNRI) Cymbalta Capsules 20 mg and 30 mg (duloxetine HCl) for the treatment of depression. Shionogi aims at sales of ¥25.0 billion in 2014, the final...read more